Our Pricing

BNF Orlistat: Comprehensive Prescribing Guidance and UK Availability

The BNF orlistat monograph provides essential prescribing information for this lipase inhibitor licensed for weight management in the UK. As a UK-registered pharmacy with over a decade of experience dispensing orlistat, we've supported thousands of patients through evidence-based weight loss programmes. This guide translates BNF guidance into practical advice for patients and prescribers, covering dosing, contraindications, and real-world efficacy data.

BNF Orlistat Indications and Licensed Use

According to BNF orlistat guidance, this medication is indicated for weight management in adults with a body mass index (BMI) of 30 kg/m² or above, or 28 kg/m² in the presence of other risk factors such as type 2 diabetes or hypertension [1]. The British National Formulary specifies orlistat should be used as an adjunct to a reduced-calorie diet and increased physical activity, not as monotherapy.

Clinical trial data cited in the BNF demonstrates that orlistat 120 mg three times daily, when combined with lifestyle modification, produces an average weight loss of 2.9 kg more than placebo over 12 months [2]. At Cured Pharmacy, every orlistat prescription requires assessment by our UK-registered clinical team to ensure BMI criteria and contraindications are properly evaluated before dispensing.

The BNF notes orlistat is the only lipase inhibitor licensed in the UK for obesity management. Unlike systemic appetite suppressants, orlistat works locally in the gastrointestinal tract by inhibiting pancreatic and gastric lipases, reducing dietary fat absorption by approximately 30% [3]. This mechanism means orlistat is not absorbed systemically, offering a distinct safety profile compared to centrally-acting weight loss medications.

BNF Orlistat Dosing and Administration Guidance

The BNF orlistat dosing schedule is straightforward: 120 mg capsule taken immediately before, during, or up to one hour after each main meal containing fat [1]. If a meal is missed or contains no fat, the dose should be omitted. This thrice-daily regimen aligns with typical UK eating patterns of three main meals.

BNF guidance emphasises that orlistat should be discontinued after 12 weeks if patients have not lost at least 5% of their initial body weight from the start of treatment [2]. This evidence-based stopping rule, recommended by NICE and reflected in the BNF, ensures patients continue treatment only if demonstrating meaningful response. Our clinical team at Cured Pharmacy monitors weight loss progress at regular intervals to apply this criterion appropriately.

The BNF also notes a lower-strength 60 mg orlistat formulation is available over-the-counter for adults with BMI 28 kg/m² or above, while the 120 mg strength discussed here requires prescription. At £12.00 for prescription-strength orlistat through our pharmacy, patients receive the full 120 mg dose under prescriber supervision, ensuring optimal efficacy and safety monitoring.

BNF Orlistat and Multivitamin Supplementation

The BNF orlistat monograph specifically advises patients to take a multivitamin supplement at bedtime, at least two hours after the evening orlistat dose [3]. This recommendation addresses orlistat's reduction in absorption of fat-soluble vitamins (A, D, E, and K). Our pharmacists routinely counsel patients on this important adjunct therapy to prevent nutritional deficiencies during treatment.

BNF Orlistat Contraindications and Cautions

The BNF orlistat entry lists several absolute contraindications: chronic malabsorption syndrome, cholestasis, and hypersensitivity to orlistat or any excipients [1]. These contraindications reflect orlistat's mechanism of action—patients with pre-existing malabsorption would experience worsened nutritional status, while cholestasis patients require normal fat digestion for bile flow.

BNF cautions include use in patients with diabetes mellitus, as weight loss may improve glycaemic control and necessitate adjustment of antidiabetic medication [2]. We've observed this clinically at Cured Pharmacy, where patients on metformin or sulfonylureas sometimes require dose reductions as orlistat-assisted weight loss improves insulin sensitivity. Our prescribers coordinate with patients' GPs to ensure safe medication titration.

The BNF also cautions about potential interactions with ciclosporin, warfarin, and antiepileptic drugs. Orlistat may alter absorption of these medications, requiring monitoring and possible dose adjustment [3]. During our online consultation, we screen for these interactions and provide specific counselling on timing of doses to minimise risk.

BNF Orlistat Side Effects and Management

The BNF orlistat side effects profile is dominated by gastrointestinal symptoms directly related to its mechanism: oily spotting, flatus with discharge, faecal urgency, fatty or oily stools, and increased defecation [4]. These effects occur in up to 27% of patients in clinical trials and are most pronounced when dietary fat intake exceeds 30% of total calories.

Importantly, the BNF notes these gastrointestinal side effects often diminish with continued use and can be minimised by adhering to a low-fat diet (less than 30% calories from fat). This creates a behavioural reinforcement mechanism—patients who consume high-fat meals experience unpleasant symptoms, encouraging dietary compliance. Our pharmacists provide detailed dietary guidance to help patients optimise tolerability while maintaining nutritional adequacy.

Rare but serious adverse effects listed in the BNF include severe liver injury (hepatocellular or mixed hepatocellular-cholestatic), which has led to acute liver failure in isolated cases [4]. The BNF advises discontinuing orlistat and seeking medical attention if signs of hepatic dysfunction develop (jaundice, dark urine, pruritus, abdominal pain). At Cured Pharmacy, we counsel all patients on these warning signs during initial dispensing.

BNF Orlistat and Renal Oxalate Nephropathy

The BNF orlistat monograph includes a warning about rare cases of oxalate nephropathy, which may lead to renal failure [4]. This occurs because orlistat-induced fat malabsorption increases colonic permeability to oxalate, raising urinary oxalate excretion. Patients with pre-existing renal impairment or those prone to kidney stones should be monitored carefully, and adequate hydration should be emphasised.

BNF Orlistat Drug Interactions

The BNF orlistat interactions section highlights several clinically significant drug-drug interactions. Orlistat may reduce absorption of ciclosporin, potentially leading to subtherapeutic immunosuppression [5]. The BNF recommends administering ciclosporin at least two hours before or after orlistat and monitoring ciclosporin blood levels more frequently.

Warfarin interaction is another BNF-listed concern: orlistat may alter vitamin K absorption, potentially affecting anticoagulation control [5]. Patients on warfarin should have their INR monitored more closely when starting or stopping orlistat. Our clinical team flags these interactions during assessment and coordinates with patients' anticoagulation clinics when necessary.

The BNF also notes orlistat may reduce absorption of fat-soluble antiepileptic drugs like lamotrigine and valproate, though clinical significance remains unclear [5]. Additionally, orlistat may enhance the effect of antidiabetic drugs through weight-loss-mediated improvements in insulin sensitivity. These interactions underscore the importance of our comprehensive medication review during the online consultation process.

BNF Orlistat Pregnancy, Breastfeeding, and Special Populations

The BNF orlistat pregnancy category states the manufacturer advises avoiding use during pregnancy, as there is limited human data and weight loss is not recommended during pregnancy [6]. Animal studies have not demonstrated teratogenicity, but the lack of established safety means orlistat should only be used if clearly necessary and under specialist supervision.

Regarding breastfeeding, the BNF notes the manufacturer advises avoiding orlistat as it is not known whether orlistat is excreted in human milk [6]. Given orlistat's minimal systemic absorption (less than 1% of an oral dose), theoretical risk to the nursing infant is low, but the precautionary principle applies. Our prescribers screen all female patients of childbearing age for pregnancy and breastfeeding status before approving orlistat prescriptions.

The BNF provides no specific dose adjustment guidance for elderly patients or those with hepatic or renal impairment, as orlistat has minimal systemic absorption [1]. However, elderly patients may be more susceptible to gastrointestinal side effects and should be counselled accordingly. At £12.00 through Cured Pharmacy with free prescriber consultation, patients receive individualised assessment regardless of age or comorbidities, with £20 off first orders using code Weightlossnew.

BNF Orlistat in Adolescents

The BNF orlistat entry notes use in children aged 12-18 years is restricted to specialist initiation only [6]. This reflects the complex medical, psychological, and developmental considerations in paediatric obesity management. Cured Pharmacy's service is limited to adults aged 18 and over, in line with our clinical governance framework and prescribing protocols.

Scientific References

1. Joint Formulary Committee. (2024). British National Formulary (BNF) 87. London: BMJ Group and Pharmaceutical Press.
2. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161.
3. Guerciolini, R. (1997). Mode of action of orlistat. International Journal of Obesity, 21(Suppl 3), S12-S23.
4. Medicines and Healthcare products Regulatory Agency. (2011). Orlistat: adverse hepatic effects. Drug Safety Update, 4(10), A1.
5. Zhi, J., Moore, R., Kanitra, L., & Mulligan, T. E. (2002). Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Journal of Clinical Pharmacology, 42(9), 1011-1019.
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). London: NICE.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.